ValuEngine Downgrades United Therapeutics (NASDAQ:UTHR) to Sell

Share on StockTwits

United Therapeutics (NASDAQ:UTHR) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Tuesday, ValuEngine reports.

Several other research analysts have also weighed in on UTHR. TheStreet upgraded shares of United Therapeutics from a “c+” rating to a “b-” rating in a report on Monday, February 11th. Cowen reiterated a “hold” rating and set a $109.00 price objective on shares of United Therapeutics in a report on Wednesday, February 27th. LADENBURG THALM/SH SH set a $124.00 price objective on shares of United Therapeutics and gave the stock a “hold” rating in a report on Thursday, February 28th. Barclays cut their price objective on shares of United Therapeutics from $100.00 to $95.00 and set an “underweight” rating on the stock in a report on Friday, March 1st. Finally, BidaskClub upgraded shares of United Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, March 1st. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company’s stock. United Therapeutics has a consensus rating of “Hold” and an average price target of $129.00.

Shares of UTHR stock opened at $80.31 on Tuesday. The stock has a market cap of $3.59 billion, a PE ratio of 6.00 and a beta of 1.15. United Therapeutics has a 1-year low of $79.40 and a 1-year high of $130.00. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.84 and a current ratio of 7.19.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported ($11.32) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $2.64 by ($13.96). The company had revenue of $362.70 million for the quarter, compared to analysts’ expectations of $335.72 million. United Therapeutics had a negative return on equity of 5.78% and a negative net margin of 9.36%. The company’s revenue was down 6.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $3.76 earnings per share. Analysts forecast that United Therapeutics will post -5.03 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Louisiana State Employees Retirement System raised its holdings in United Therapeutics by 0.9% in the first quarter. Louisiana State Employees Retirement System now owns 11,700 shares of the biotechnology company’s stock valued at $1,373,000 after buying an additional 100 shares during the period. Oak Associates Ltd. OH raised its stake in shares of United Therapeutics by 2.3% during the first quarter. Oak Associates Ltd. OH now owns 4,675 shares of the biotechnology company’s stock valued at $549,000 after purchasing an additional 105 shares during the period. First Mercantile Trust Co. raised its stake in shares of United Therapeutics by 47.8% during the fourth quarter. First Mercantile Trust Co. now owns 340 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 110 shares during the period. Arizona State Retirement System raised its stake in shares of United Therapeutics by 0.4% during the first quarter. Arizona State Retirement System now owns 31,395 shares of the biotechnology company’s stock valued at $3,685,000 after purchasing an additional 111 shares during the period. Finally, Utah Retirement Systems raised its stake in shares of United Therapeutics by 1.5% during the first quarter. Utah Retirement Systems now owns 8,087 shares of the biotechnology company’s stock valued at $949,000 after purchasing an additional 122 shares during the period. Hedge funds and other institutional investors own 96.47% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Further Reading: What is a resistance level?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Alliance Data Systems Co.  Receives Average Rating of “Hold” from Brokerages
Alliance Data Systems Co. Receives Average Rating of “Hold” from Brokerages
Host Hotels and Resorts Inc  Receives Consensus Recommendation of “Buy” from Analysts
Host Hotels and Resorts Inc Receives Consensus Recommendation of “Buy” from Analysts
Weir Group PLC  Given Consensus Rating of “Buy” by Analysts
Weir Group PLC Given Consensus Rating of “Buy” by Analysts
ViaSat, Inc.  Receives $96.99 Average Target Price from Analysts
ViaSat, Inc. Receives $96.99 Average Target Price from Analysts
Carrefour SA  Given Consensus Rating of “Hold” by Brokerages
Carrefour SA Given Consensus Rating of “Hold” by Brokerages
RTL Group S.A.  Receives €53.23 Consensus Target Price from Analysts
RTL Group S.A. Receives €53.23 Consensus Target Price from Analysts


© 2006-2019 Ticker Report